Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
CAMBRIDGE, Mass., Feb. 03, 2016 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the Leerink Partners 5th Annual Global Healthcare Conference in New York on Wednesday, February 10, 2016 at 11:30 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at agios.com.
Contact: Renee Leck, Senior Manager, Investor and Public Relations [email protected] 617-649-8299
